These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 2866140)

  • 21. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K; Shrieve DC
    J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of glutathione (GSH) depletion in vivo by buthionine sulfoximine (BSO) on the radiosensitization of SR 2508.
    Kramer RA; Soble M; Howes AE; Montoya VP
    Int J Radiat Oncol Biol Phys; 1989 May; 16(5):1325-9. PubMed ID: 2523885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation.
    Drew R; Miners JO
    Biochem Pharmacol; 1984 Oct; 33(19):2989-94. PubMed ID: 6148944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
    Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
    Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
    Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
    J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of acute exercise on glutathione deficient heart.
    Leeuwenburgh C; Leichtweis S; Hollander J; Fiebig R; Gore M; Ji LL
    Mol Cell Biochem; 1996 Mar; 156(1):17-24. PubMed ID: 8709971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of modulation of hepatic glutathione on biotransformation and covalent binding of aflatoxin B1 to DNA in the mouse.
    Monroe DH; Eaton DL
    Toxicol Appl Pharmacol; 1988 Jun; 94(1):118-27. PubMed ID: 3131927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exogenous glutathione attenuates the antiproliferative effect of buthionine sulfoximine.
    Kang YJ
    Toxicology; 1994 Mar; 88(1-3):177-89. PubMed ID: 8160199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
    Kable EP; Favier D; Parsons PG
    Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 1,2-Dichloropropane (DCP) toxicity is correlated with DCP-induced glutathione (GSH) depletion and is modulated by factors affecting intracellular GSH.
    Imberti R; Mapelli A; Colombo P; Richelmi P; Bertè F; Bellomo G
    Arch Toxicol; 1990; 64(6):459-65. PubMed ID: 1980407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
    Kang YJ
    Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
    Yu NY; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1265-9. PubMed ID: 6236185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of buthionine sulfoximine on the glutathione level in goldfish tissues.
    Lushchak VI; Hermes-Lima M
    Ukr Biokhim Zh (1999); 2005; 77(3):35-8. PubMed ID: 16566126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of in utero administration of buthionine sulfoximine on rat development.
    Reyes E; Ott S; Robinson B; Contreras R
    Pharmacol Biochem Behav; 1995 Apr; 50(4):491-7. PubMed ID: 7617692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Depletion of intracellular GSH and NPSH by buthionine sulfoximine and diethyl maleate: factors that influence enhancement of aerobic radiation response.
    Varnes ME; Biaglow JE; Roizin-Towle L; Hall EJ
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1229-33. PubMed ID: 6469743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
    Shrieve DC; Denekamp J; Minchinton AI
    Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective depletion of glutathione in rat striatum and substantia nigra by L-buthionine sulfoximine in combination with 2-cyclohexene-1-one.
    Pileblad E; Magnusson T
    Life Sci; 1990; 47(25):2333-42. PubMed ID: 2263161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depletion of glutathione by L-buthionine sulfoximine does not promote inactivation of myo-inositol transport in cultured bovine lens epithelial cells.
    Cammarata PR; Tse D; Yorio T
    Curr Eye Res; 1991 Apr; 10(4):321-30. PubMed ID: 1676962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the protective effect of cyclophosphamide by pre-treatment with buthionine sulfoximine.
    Carmichael J; Friedman N; Tochner Z; Adams DJ; Wolf CR; Mitchell JB; Russo A
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1191-3. PubMed ID: 3744939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.